Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Related Keywords

Australia ,Louisiana ,United States ,Taiwan ,New Orleans ,Shanghai ,China ,Hong Kong ,Singapore ,Beijing ,South Korea ,American ,Jay Mei ,Asia Pacific ,Peter Qian ,American Society Of Hematology ,Company Annual ,Antengene Corporation ,Hong Kong Stock Exchange ,Antengene Corporation Limited ,Plus Gemox Regimen ,Heavily Pretreated Patients ,Cell Lymphoma ,Phase Ib Touch ,Preliminary Results ,Launch Study ,Open Label Study ,Refractory Multiple ,Corporation Limited ,Patients Beyond ,Greater China ,Annual Report ,Hong Kong Stock ,